Bioconjugation Services CDMOs in Asia-Pacific
8 published
8 published CDMOs match Bioconjugation Services in Asia-Pacific.
Facilities in this set are in Shanghai, Hangzhou, Singapore, Beijing, Bengaluru, and China.
Capabilities that show up most often in this set: Antibody-Drug Conjugate (ADC), Biologics (Monoclonal Antibodies), Biologics (Other), Peptide, and Small Molecule.
Matching companies
Altruist BiologicsGlobal CDMO offering end-to-end development and GMP manufacturing for monoclonal antibodies, bispecific antibodies, fusion proteins, recombinant proteins, and antibody-drug conjugates, with facilities in Suzhou and Hangzhou featuring up to 20,000-liter bioreactors.
Carbogen AmcisFull-service CDMO offering integrated drug substance and sterile drug product development and manufacturing from early phase through commercialization, with specialized capabilities in API synthesis, process development, analytical services, and stability testing across multiple scales.
LOTTE BiologicsLOTTE Biologics offers biologics CDMO services spanning process and analytical development, antibody manufacturing from clinical to commercial GMP, and bioconjugate manufacturing. Its operations are based at campuses in Syracuse, New York and Songdo, Incheon.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Piramal Pharma SolutionsCDMO specializing in HPAPIs, ADCs, peptides, vaccines, and biologics with 4,700+ team members across 15 global sites and 500+ customers. Offers integrated development and manufacturing with backward integration capabilities and global program management.
PortonPorton is a global CDMO offering integrated manufacturing and development services across small molecules, peptides, oligonucleotides, biologics, and conjugates with specialized capabilities in flow chemistry, biocatalysis, and advanced therapies.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
WuXi XDCWuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.
Markdown mirror: /services/bioconjugation/apac.md